Product classification

64603-91-4

Product Name：Isoxazolo[5,4-c]pyridin-3(2H)-one,4,5,6,7-tetrahydro-
Molecular Formula：C6H8 N2 O2
Purity：99%
Molecular Weight：

Inquiry

Product Details;

CasNo： 64603-91-4

Molecular Formula： C6H8 N2 O2

Appearance： white solid

64603-91-4 Properties

Molecular Formula:C6H8 N2 O2
Molecular Weight:140.142
Appearance/Colour:white solid
Vapor Pressure:0.00113mmHg at 25°C
Melting Point:242-244° (dec)
Boiling Point:340.5 °C at 760 mmHg
PKA:pKa (water, 25°): 4.44 ±0.03; 8.48 ±0.04
Flash Point:159.7 °C
PSA：58.29000
Density:1.36 g/cm³
LogP:1.15670

64603-91-4 Usage

Description

Gaboxadol HCl (64603-91-4) is a GABA-A receptor agonist. Hypnotic agent.

Uses

GABAa agonist, GABAc antagonist

Biological Activity

Systemically active GABA A receptor agonist and GABA C receptor antagonist. Displays antinociceptive, anticonvulsant and sedative effects. Hypnotic agent that enhances delta activity within non-REM sleep in rats.

References

1) Meera et al. (2011), Molecular basis for the high THIP/gaboxadol sensitivity of extrasynaptic GABA(A) receptors; J. Neurophysiol., 106 2057

InChI:InChI=1/C6H8N2O2.ClH/c9-6-4-1-2-7-3-5(4)10-8-6;/h7H,1-3H2,(H,8,9);1H

64603-91-4 Relevant articles

GABOXADOL FORMS, COMPOSITIONS THEREOF, AND RELATED METHODS

-

Page/Page column 27, (2008/06/13)

The invention provides novel gaboxadol forms. These forms include salts, hydrates, solvates, and polymorphs of gaboxadol. The invention also provides novel compositions comprising these novel soluble forms and a suitable carrier. The invention also provides related methods of treatment. Compositions and methods of the invention of the invention have a number of uses, including the treatment or prevention of sleep disorders.

Polymorphic forms of a GABAA agonist

-

Page/Page column 5, (2008/06/13)

Two new crystalline monhydrates and two new crystalline anhydrates of gaboxadol are disclosed together with methods for preparing them.

Heterocyclic compounds

-

, (2008/06/13)

The compound Ia STR1 has been shown to possess GABA-related activity. The invention relates to Ia and derivatives thereof, covered by the formula STR2 in which R" is hydrogen, acetyl or a group of the general formula STR3 in which R5 is C1-8 alkyl; phenyl; phenyl substituted in the 4-position with halogen, lower alkoxy, or lower alkyl; or phenylalkyl in which the phenyl group may be substituted in the 4-position with halogen, lower alkoxy, or lower alkyl; and salts thereof. Novel intermediates for preparing I are STR4 in which Alk is a lower alkyl group and Z is hydrogen or an amino-protecting group; STR5 wherein Z is hydrogen or an amino-protecting group, T is a group convertible, by hydrolysis, into an oxy group, and Q is a leaving group which, on reaction with hydroxylamine, forms a hydroxamic acid group; STR6 wherein Z and T are as defined above; STR7 wherein Z is as defined above, and W is hydrogen or a group removable to yield the free hydroxy group, with the proviso that at least one of Z and W is different from hydrogen.

64603-91-4 Process route

: 3-hydroxy-4,5,6,7-tetrahydro-1,2-oxazolo-[5,4-c]pyridin-6-ium chloride

: 64603-91-4
4,5,6,7-tetrahydroisoxazole<5,4-c>pyridin-3-ol

Conditions

Conditions	Yield
With triethylamine; In ethanol; water; at 5 ℃; for 2h;

: 815574-58-4
4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol monohydrate

: 64603-91-4
4,5,6,7-tetrahydroisoxazole<5,4-c>pyridin-3-ol